C Marchetti1, A Fagotti2, V Tombolini3, G Scambia4, F De Felice5. 1. Department of Woman and Child Sciences, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy. Electronic address: claudia.marchetti@policlinicogemelli.it. 2. Department of Woman and Child Sciences, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; Catholic University of the Sacred Heart, Rome, Italy. Electronic address: anna.fagotti@policlinicogemelli.it. 3. Department of Radiotherapy, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy. Electronic address: vincenzo.tombolini@uniroma1.it. 4. Department of Woman and Child Sciences, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; Catholic University of the Sacred Heart, Rome, Italy. Electronic address: giovanni.scambia@policlinicogemelli.it. 5. Department of Radiotherapy, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy. Electronic address: francesca.defelice@uniroma1.it.
Abstract
PURPOSE: Neoadjuvant chemotherapy followed by surgery (NACT + S) has been compared with definitive chemoradiothherapy (CRT) in randomized clinical trials (RCTs) in stage IB2, IIA and IIB cervical cancer (1994 Figo stage). Our aim was to evaluate efficacy and toxicity of NACT + S and CRT and identify differences in clinical outcomes and severe toxicity frequency. METHODS: The PRISMA statement was applied. Random-effects models were used. RESULTS: Two RCTs representing 1259 patients were identified. NACT + S was not associated with significant OS improvement compared with CRT, with HR of 1.08 (95% CI = 0.86-1.36; p = 0.51). The HR of relapse was 1.32 (95%CI = 1.07-1.62) in favor of CRT. Severe acute toxicity was lower in CRT group. CONCLUSION: This meta-analysis showed similar OS rates between treatment and CRT superiority over NACT + S in terms of DFS and severe acute toxicity. Impact on long term toxicity and quality of life remain to be proven.
PURPOSE: Neoadjuvant chemotherapy followed by surgery (NACT + S) has been compared with definitive chemoradiothherapy (CRT) in randomized clinical trials (RCTs) in stage IB2, IIA and IIB cervical cancer (1994 Figo stage). Our aim was to evaluate efficacy and toxicity of NACT + S and CRT and identify differences in clinical outcomes and severe toxicity frequency. METHODS: The PRISMA statement was applied. Random-effects models were used. RESULTS: Two RCTs representing 1259 patients were identified. NACT + S was not associated with significant OS improvement compared with CRT, with HR of 1.08 (95% CI = 0.86-1.36; p = 0.51). The HR of relapse was 1.32 (95%CI = 1.07-1.62) in favor of CRT. Severe acute toxicity was lower in CRT group. CONCLUSION: This meta-analysis showed similar OS rates between treatment and CRT superiority over NACT + S in terms of DFS and severe acute toxicity. Impact on long term toxicity and quality of life remain to be proven.
Authors: Geetu Bhandoria; T S Shylasree; Prashant Bhandarkar; Vijay Ahuja; Amita Maheshwari; Rupinder Sekhon; S P Somashekhar Journal: Indian J Gynecol Oncol Date: 2020-06-15